IN THE SPOTLIGHT

Phase 1 Trial of SEZ6-Targeting Antibody-Drug Conjugate Shows Manageable Safety and Efficacy in Small Cell Lung Cancer

Phase 1 Trial of SEZ6-Targeting Antibody-Drug Conjugate Shows Manageable Safety and Efficacy in Small Cell Lung Cancer

EUROPEAN COMMISSION APPROVES AMGEN’S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

EUROPEAN COMMISSION APPROVES AMGEN’S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Amgen |

Amgen |

European Commission Approves IMDYLLTRA: A Breakthrough for Small Cell Lung Cancer Treatment

European Commission Approves IMDYLLTRA: A Breakthrough for Small Cell Lung Cancer Treatment

SystImmune Unveils Encouraging Phase 1 Results for BL-M14D1 in Small-Cell Lung Cancer at ASCO 2026

SystImmune Unveils Encouraging Phase 1 Results for BL-M14D1 in Small-Cell Lung Cancer at ASCO 2026

62,000 New Small Cell Lung Cancer Cases Diagnosed in Europe

62,000 New Small Cell Lung Cancer Cases Diagnosed in Europe

Molecular Partners Spotlights Radio-DARPin Strategy as MP0712 Trial Advances

Molecular Partners Spotlights Radio-DARPin Strategy as MP0712 Trial Advances

Misty Dawn Shields: Fabulous “Research to Practice” session on updates in Small Cell Lung Cancer

Misty Dawn Shields: Fabulous “Research to Practice” session on updates in Small Cell Lung Cancer

Whitehawk Therapeutics’ ASCO 2026 Presentation Confirms SEZ6 as Highly Expressed Target in Small Cell Lung Cancer

Whitehawk Therapeutics’ ASCO 2026 Presentation Confirms SEZ6 as Highly Expressed Target in Small Cell Lung Cancer

Precision, Partnership, Purpose: Lung Cancer Highlights from AACR 2026

Precision, Partnership, Purpose: Lung Cancer Highlights from AACR 2026

The American Association for Cancer Research (AACR) Annual Meeting brought together thousands of cancer researchers, clinicians, advocates, and patients in San Diego from April 17–22. This year's theme—“Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally”—set a powerful tone for a meeting that showcased advances across the lung cancer landscape.  One message was loud and clear. Science is accelerating, and we are reimagining how healthcare is delivered. From…

Podcast: Making the Most of Your Healthcare Visits

Podcast: Making the Most of Your Healthcare Visits

How do you make the most of your visits with your healthcare team? In this episode, lung cancer survivor Bill Morris shares his experience with lung cancer and how he approaches his healthcare visits now. Oncology nurse practitioner Rasheda Persinger shares her insights after 20 years of working with patients. Hosts Ann and Dr. Shields discuss with Bill and Rasheda what they wish every patient knew, from writing down questions before an appointment to asking about biomarker testing to why…

Small Cell SMASHERS Fireside Chat with Dr. Simon Heeke

Small Cell SMASHERS Fireside Chat with Dr. Simon Heeke

In May, we were joined by Simon Heeke, PhD, MD Anderson Cancer Center. Dr. Heeke discussed biomarker identification and their potential roles in patients impacted by SCLC.Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Smart & Practical Tips From a Financial Navigator

Smart & Practical Tips From a Financial Navigator

LUNGevity offers a variety of virtual support groups called ‘meetups’ where lung cancer survivors and caregivers connect with others who understand the patient experience.Each month, an expert is invited to share information on a topic relevant to life with lung cancer, engage with attendees, and answer questions in real time. When the expert talk concludes, the focus shifts to survivor sharing and updates.The following video is a recording from a session with an expert during a LUNGevity…

Watch Small Cell SMASHERS Live Sessions from HOPE Summit 2026

Watch Small Cell SMASHERS Live Sessions from HOPE Summit 2026

At HOPE Summit 2026—for the first time ever—we hosted Small Cell SMASHERS Live sessions with Misty Shields, MD, PhD, Indiana University School of Medicine. We recorded these sessions so everyone in the Small Cell Lung Cancer community can access the valuable information shared. Small Cell SMASHERS Live Recorded Sessions Blazing New Trails in SCLC: Exploring Genetics & Biology  Deep in the Heart of Research: Texas-Sized SCLC Advances  The New Frontier: FDA…

Watch HOPE Summit 2026 Videos

Watch HOPE Summit 2026 Videos

HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.For the second year in a row, select sessions were recorded so those who could not attend are still able to access the valuable information shared.HOPE Summit 2026 Recorded Sessions Keynote: Wagons Roll with Dr. Ross Camidge  Back in the Saddle: Reclaiming Strength and Living Well …

Small Cell SMASHERS Fireside Chat with Dr. Catherine Meador

Small Cell SMASHERS Fireside Chat with Dr. Catherine Meador

In April, we were joined by Catherine Meador, MD, PhD, assistant professor of medicine at Harvard Medical School. Dr. Meador discussed Transformed SCLC: Understanding Biology, Detection, and Identifying Novel Targets. Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.

Clinical Trial Access Isn’t Expanding. It’s Concentrating.

Clinical Trial Access Isn’t Expanding. It’s Concentrating.

Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung cancer community, the people who enroll in the trials need to represent the populations who are diagnosed in everyday life.Recognizing these needs, federal agencies like the United States Food and Drug Administration (FDA) have been encouraging clinical trials to offer more locations across the US.The PlanThe intention…

Podcast: Why Community Matters in Lung Cancer Care

Podcast: Why Community Matters in Lung Cancer Care

Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to lung cancer to her own diagnosis, as well as her work building patient communities around the world. She discusses how connecting with others has shaped her journey and why community is important for support, information, and advocacy.Hosts Ann Steagall, RN, BSN, and Misty Shields, MD, PhD, explore with Jill how…

Podcast: Lung Cancer Diagnosis—What Happens Next

Podcast: Lung Cancer Diagnosis—What Happens Next

What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from initial scans and biopsies through multiple treatments, and the moment a later biopsy revealed a biomarker that led to a targeted therapy.Hosts Ann Steagall and Misty Shields, MD, PhD, then speak with Anne Chiang, MD, PhD, thoracic oncologist at Yale University, about what patients can expect at their first visit,…

Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss

Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss

This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who understand them and what they’re going through.Periodically, we invite an expert to speak on a topic at the beginning of a meetup, with the second half dedicated to questions and conversation. Visit the online calendar to see our virtual meetups and other upcoming events.For this meetup, we welcomed Jenna Doyle Ruhl and…

Meet The “Mini-Organs” of Lung Cancer Research

Meet The “Mini-Organs” of Lung Cancer Research

Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their new puppy brings a smile. We interact with our environment every moment of the day. And so do lung cancer cells.  A Brief HistoryTraditionally, we have studied tumor cells in isolation. We often study single cells in a petri dish, or under a microscope, to understand how they work. This has been very important and…

Explaining BiTE® Therapy

Explaining BiTE® Therapy

 A bi-specific T-cell engager (BiTE®) is a new type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the body’s immune response, to attack tumor cells. There is currently one FDA-approved BiTE® therapy treatment for targeting small cell lung cancer (SCLC).The video below was created to give you clear, easy-to-understand information about bi-specific T-cell engagers, so you can feel more informed and prepared as you…

Small Cell SMASHERS Fireside Chat with Dr. Laura Alder

Small Cell SMASHERS Fireside Chat with Dr. Laura Alder

In March, we were joined by Laura Alder, MD, assistant professor of medicine in the Division of Medical Oncology at Duke University Medical Center, to discuss the topic of managing brain metastases in SCLC.Moderated by Misty Shields, MD, PhD, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.

Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer

Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer

Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a sobering reminder that our work is far from over.The Big Picture Shows Real ProgressLet’s start with the good news. We have made significant strides in cancer care over the past three decades. Since 1991, the cancer death rate has dropped by 34%. This translates to approximately 4.8 million…

Artificial Intelligence in Lung Cancer: Hope vs. Hype

Artificial Intelligence in Lung Cancer: Hope vs. Hype

Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions.AI has evolved from early consumer tools (like autocorrect on phones, customer service chatbots, and personalized shopping recommendations) to advanced systems with the potential to revolutionize biomedical discovery and patient care. While there is tremendous excitement around AI, there is also a critical need to use it responsibly.Researchers are actively…

Small Cell SMASHERS Fireside Chat with Dr. Eric Singhi

Small Cell SMASHERS Fireside Chat with Dr. Eric Singhi

Eric Singhi, MD, assistant professor, University of Texas MD Anderson Cancer Center, joined us to discuss the role of community and support in people with small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.

Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It

Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It

The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting healthy tissue. But sometimes, the checks and balances get confused and stop the immune system from doing what’s right—such as killing tumor cells.  Tumor cells are good at confusing the immune system because they originate from our healthy cells. They can often avoid detection by immune cells. Through several…

New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting

New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting

The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused on multidisciplinary research aiming to leverage the immune system to improve outcomes for cancer patients, including  several exciting areas of growth in lung cancer-directed immunotherapy.Tumor Imaging is Growing More Powerful  Advanced imaging techniques are poised to change how we understand and treat…

The Future of Lung Cancer Starts Here

The Future of Lung Cancer Starts Here

For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested  $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…

Biggest News from Berlin: Research Highlights from ESMO

Biggest News from Berlin: Research Highlights from ESMO

Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data.  We saw data from studies that aim to build upon…